P09.25 Identifying the correct patient (pt) population for ABT414: biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)

Aim: Aberrant EGFR signaling plays a vital role in GBM oncogenesis. ABT414 comprises an EGFR targeted antibody conjugated to the toxic agent monomethylauristatin F. An open label, 3 arm, phase I study (NCT01800695) is underway to evaluate 3 different ABT414 regimens in GBM. To understand the populat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Lassman, A., Gan, H., Robert-Rapp, L., Ansell, P., Merrell, R., Kumthekar, P., Gomez, E., Holen, K., Reardon, D., van den Bent, M.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
POSTER PRESENTATIONS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464164/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.281
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares